151 Participants Needed

F14 for Postoperative Pain After Knee Replacement

Recruiting at 6 trial locations
MS
Overseen ByMatthew Shive, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Arthritis Innovation Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests if injecting a long-lasting painkiller called celecoxib into the knee can help reduce pain for patients having knee replacement surgery. The medication works by blocking chemicals that cause pain and swelling. Celecoxib has been shown to be effective in reducing pain and improving function in patients with knee osteoarthritis.

Will I have to stop taking my current medications?

Yes, you will need to stop taking certain medications. You must discontinue nonsteroidal anti-inflammatory drugs (NSAIDs), medical or recreational marijuana, cannabidiol (CBD), pregabalin, gabapentin, and opioid analgesics at least 7 to 10 days before the surgery and for a specified period after the surgery.

Who Is on the Research Team?

MS

Matthew Shive, PhD

Principal Investigator

Arthritis Innovation Corporation

Are You a Good Fit for This Trial?

Adults aged 45-80, with a BMI ≤ 40 kg/m2, scheduled for unilateral total knee replacement surgery can join. They must have stable health as confirmed by tests and no recent injections or major surgeries in the affected knee. Women of childbearing age need a negative pregnancy test and agree to birth control measures.

Inclusion Criteria

Capable of giving signed informed consent and complying with requirements and restrictions listed in the informed consent form (ICF) and in this protocol
My knees do not have severe inward or outward bending.
My health is good enough for surgery according to the ASA score.
See 8 more

Exclusion Criteria

You have a history of heavy drinking within the past year.
I was diagnosed with bone tissue death in the last year.
You are currently involved in a legal case related to an injury to your knee.
See 32 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single intra-articular dose of F14 (625 mg sustained release celecoxib) concurrent with multimodal analgesia during total knee replacement surgery

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-6 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • F14
Trial Overview The trial is testing F14 (a sustained release form of celecoxib) combined with standard pain management against standard treatment alone after knee replacement surgery. It's randomized and double-blind, meaning neither patients nor doctors know who gets which treatment.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: F14 + Multimodal AnalgesiaExperimental Treatment4 Interventions
Group II: Multimodal AnalgesiaActive Control3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Arthritis Innovation Corporation

Lead Sponsor

Trials
3
Recruited
270+

Allucent

Collaborator

Trials
4
Recruited
350+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security